Cargando…
The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report
BACKGROUND: Since tacrolimus ointment was approved by the U.S. Food and Drug Administration (FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30 additional countries, including numerous European Union member nations. Moreover, in the current clinical routine the...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1386691/ https://www.ncbi.nlm.nih.gov/pubmed/16405733 http://dx.doi.org/10.1186/1471-2407-6-7 |